» Articles » PMID: 24145382

1H NMR Metabolomic Signatures in Five Brain Regions of the AβPPswe Tg2576 Mouse Model of Alzheimer's Disease at Four Ages

Overview
Publisher Sage Publications
Specialties Geriatrics
Neurology
Date 2013 Oct 23
PMID 24145382
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

In the quest for biomarkers of onset and progression of Alzheimer's disease, a 1H NMR-based metabolomic study was performed on the simple single-transgenic Tg2576 mouse model. These mice develop a slow cognitive decline starting by 6 months and express amyloid plaques from 10 months of age. The metabolic profiles of extracts from five brain regions (frontal cortex, rhinal cortex, hippocampus, midbrain, and cerebellum) of Tg2576 male mice were compared to those of controls, at 1, 3, 6 and 11 months of age. The most obvious differences were due to brain regions. Age was also a discriminating parameter. Metabolic perturbations were already detected in the hippocampus and the rhinal cortex of transgenic mice as early as 1 month of age with decreased concentrations of glutamate (Glu) and N-acetylaspartate (NAA) compared to those in wild-type animals. Metabolic changes were more numerous in the hippocampus and the rhinal cortex of 3 month-old transgenic mice and involved Glu, NAA, myo-inositol, creatine, phosphocholine, and γ-aminobutyric acid (only in the hippocampus) whose concentrations decreased. A metabolic disruption characterized by an increase in the hippocampal concentrations of Glu, creatine, and taurine was detected in 6 month-old transgenic mice. At this time point, the chemical profile of the cerebellum was slightly affected. At 11 months, all the brain regions analyzed (except the frontal cortex) were metabolically altered, with mainly a marked increase in the formation of the neuroprotective metabolites creatine and taurine. Our findings demonstrate that metabolic modifications occur long before the onset of behavioral impairment.

Citing Articles

Metabolomics study to reveal cognitive improvement with treatment of Scrophularia buergeriana.

Yoon D, Oh S, Na H, Choi B, Kim K, Lee Y Sci Rep. 2024; 14(1):17007.

PMID: 39043762 PMC: 11266482. DOI: 10.1038/s41598-024-66371-9.


Estimating the synaptic density deficit in Alzheimer's disease using multi-contrast CEST imaging.

Shahid S, Dzemidzic M, Butch E, Jarvis E, Snyder S, Wu Y PLoS One. 2024; 19(3):e0299961.

PMID: 38483851 PMC: 10939256. DOI: 10.1371/journal.pone.0299961.


Neurodegenerative Changes in the Brains of the 5xFAD Alzheimer's Disease Model Mice Investigated by High-Field and High-Resolution Magnetic Resonance Imaging and Multi-Nuclei Magnetic Resonance Spectroscopy.

Yoo C, Kim J, Baek H, Chang K, Choe B Int J Mol Sci. 2023; 24(6).

PMID: 36982146 PMC: 10049146. DOI: 10.3390/ijms24065073.


Status of Metabolomic Measurement for Insights in Alzheimer's Disease Progression-What Is Missing?.

Yin C, Harms A, Hankemeier T, Kindt A, de Lange E Int J Mol Sci. 2023; 24(5).

PMID: 36902391 PMC: 10003384. DOI: 10.3390/ijms24054960.


Chronic treatment with baicalein alleviates behavioural disorders and improves cerebral blood flow via reverting metabolic abnormalities in a J20 transgenic mouse model of Alzheimer's disease.

Zhang L, Wong L, Wong P, Shen W, Yang S, Huang L Brain Behav Immun Health. 2023; 28:100599.

PMID: 36817510 PMC: 9931920. DOI: 10.1016/j.bbih.2023.100599.